Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $58.3 million.

  • Integra Lifesciences Holdings' Non-Current Deferred Tax Liability fell 1546.16% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year decrease of 1546.16%. This contributed to the annual value of $60.8 million for FY2024, which is 7188.69% down from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Non-Current Deferred Tax Liability stood at $58.3 million for Q3 2025, which was down 1546.16% from $60.1 million recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Non-Current Deferred Tax Liability registered a high of $218.3 million during Q4 2022, and its lowest value of $31.4 million during Q1 2024.
  • Its 5-year average for Non-Current Deferred Tax Liability is $85.4 million, with a median of $65.3 million in 2021.
  • Per our database at Business Quant, Integra Lifesciences Holdings' Non-Current Deferred Tax Liability skyrocketed by 92431.07% in 2021 and then tumbled by 7188.69% in 2024.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Non-Current Deferred Tax Liability stood at $169.8 million in 2021, then rose by 28.56% to $218.3 million in 2022, then fell by 0.87% to $216.4 million in 2023, then crashed by 71.89% to $60.8 million in 2024, then decreased by 4.19% to $58.3 million in 2025.
  • Its Non-Current Deferred Tax Liability was $58.3 million in Q3 2025, compared to $60.1 million in Q2 2025 and $57.6 million in Q1 2025.